The 1 analysts offering 12-month price forecasts for Silverback Therapeutics Inc have a median target of 5.00, with a high estimate of 5.00 and a low estimate of 5.00. The median estimate represents a -1.96% decrease from the last price of 5.10.
The current consensus among 2 polled investment analysts is to Hold stock in Silverback Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.35
Reporting Date Nov 09
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.